Search results for "METASTATIC"

showing 10 items of 267 documents

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis

2007

Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP) administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for i.v. administration), their efficacy and large use, some major issues have to be taken into account extendedly both by oncologists and by dentists: 1) therapeutic dental protocol for patients with diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ); 2) dental strategies for patients in former or current i.v. BF treatment and in absence of BRONJ signs; 3) strategies for patients before i.v. BF treatment. Clinical features and guidelines for the management of th…

medicine.medical_specialtyBone diseasemedicine.medical_treatmentDentistryBone NeoplasmsJaw neoplasmPatient Education as TopicmedicineHumansDental Restoration PermanentIntensive care medicineAdverse effectbisphosphonates metastatic bone diseaseBone Density Conservation AgentsDiphosphonatesbusiness.industrySurrogate endpointAdvanced stageOsteonecrosisHematologyBisphosphonatemedicine.diseaseJaw NeoplasmsOncologybusinessOsteonecrosis of the jawAnnals of Oncology
researchProduct

Imaging-Based Preoperative Planning

2017

Liver resection in the treatment of colorectal liver metastases, as for any other primary or secondary liver tumor, needs to be oncologically effective and surgically safe. Both goals need equal consideration, and imaging-based preoperative planning is paramount for achieving each of them. Preoperative imaging should ideally identify all metastatic lesions in the liver, as well as extrahepatic disease. Furthermore, it should provide an anatomical roadmap with the exact localization of each lesion within the segmental hepatic anatomy, and its proximity to adjacent vasculo-biliary structures, to allow for proper resection leaving the patient with a sufficiently functioning liver remnant. This…

medicine.medical_specialtyChemotherapyLiver tumorMetastatic lesionsPreoperative planningmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentmedicine.diseaseResectionLesionmedicineRadiologymedicine.symptombusinessLiver function testsPreoperative imaging
researchProduct

Metastatic Melanoma of the Tongue: A Rare Case

2012

Not available

medicine.medical_specialtyHistologyMetastatic melanomabusiness.industryMelanomaDermatologyGeneral Medicinemedicine.diseaseoral melanomaDermatologyPathology and Forensic Medicinemedicine.anatomical_structureSettore MED/28 - Malattie OdontostomatologicheTongueRare caseMedicineTongue NeoplasmbusinessActas Dermo-Sifiliográficas
researchProduct

A radiomics evaluation of 2D and 3D MRI texture features to classify brain metastases from lung cancer and melanoma

2017

[EN] Brain metastases are occasionally detected before diagnosing their primary site of origin. In these cases, simple visual examination of medical images of the metastases is not enough to identify the primary cancer, so an extensive evaluation is needed. To avoid this procedure, a radiomics approach on magnetic resonance (MR) images of the metastatic lesions is proposed to classify two of the most frequent origins (lung cancer and melanoma). In this study, 50 T1-weighted MR images of brain metastases from 30 patients were analyzed: 27 of lung cancer and 23 of melanoma origin. A total of 43 statistical texture features were extracted from the segmented lesions in 2D and 3D. Five predictiv…

medicine.medical_specialtyMetastatic lesionsLung Neoplasms030218 nuclear medicine & medical imagingTECNOLOGIA ELECTRONICA03 medical and health sciencesNaive Bayes classifier0302 clinical medicineRadiomicsmedicineHumansLung cancerMelanomaSite of originmedicine.diagnostic_testbusiness.industryBrain NeoplasmsMelanomaMagnetic resonance imagingBayes Theoremmedicine.diseasePrimary cancerMagnetic Resonance Imaging030220 oncology & carcinogenesisRadiologybusiness
researchProduct

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas

2008

Introduction Despite many efforts to develop new chemotherapies for metastatic upper gastrointestinal (GI) cancer, overall prognosis continues to be fatal, particularly in gastric and pancreatic cancer. Many of these patients deserve second-or third-line treatment after failure of first-line chemotherapy. Therefore, we analysed toxicity and response rate of weekly docetaxel after failed upfront regimes in these upper GI cancer patients. Patients and Methods Between 2001 and 2006, 18 patients received docetaxel based regimes (35 mg/m2 weekly) after informed consent. Response rates were determined using RECIST criteria or tumor progression if clinically evident. Toxicities were graded based o…

medicine.medical_specialtyPathologymedicine.medical_treatmentSalvage therapyNeutropeniachemotherapygastriclcsh:RC254-282GastroenterologysalvageInternal medicinePancreatic cancermedicinedocetaxelOriginal ResearchChemotherapyLeukopeniabusiness.industryCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemetastaticRegimenOncologyDocetaxelmedicine.symptombusinessmedicine.drugClinical medicine. Oncology
researchProduct

Oral capecitabine and Vinorelbine in Metastatic Breast Cancer. A Retrospective Analysis of Tolerability and Activity

2012

ABSTRACT Background The purpose of this study was to retrospectively analyze toxicity profile and activity of an all-oral combination schedule of Capecitabine (Cape) and Vinorelbine (VNR) in metastatic breast cancer (MBC) patients (pts). Methods All pts treated had a histological confirmed diagnosis of breast cancer (BC). Each 3-week cycle of treatment consisted of 500 mg/m2 cape twice daily (2 weeks on, 1 week off), and 60 mg/m2 VNR on days 1 and 8. Results From June'07 to December'11 we analyzed 77 MBC pts. Median age was 52 years (range 34-73). 58 pts (75,3%) had a performance status (PS) ECOG 0; 13 pts (16,8%) PS1, 6 pts (7,8%) PS2. 5 pts (6,5%) had metastatic disease at time of diagnos…

medicine.medical_specialtyPerformance statusbusiness.industrymacromolecular substancesHematologyNeutropeniamedicine.diseaseVinorelbineMetastatic breast cancerGastroenterologycarbohydrates (lipids)Capecitabinestomatognathic diseasesRegimenBreast cancerOncologyInternal medicineotorhinolaryngologic diseasesmedicinebacteriaProgression-free survivalbusinessmedicine.drugAnnals of Oncology
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma

2018

medicine.medical_specialtySkin NeoplasmsMetastatic melanomaBiopsyTreatment outcomeDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineX ray computedBiopsymedicineHumansNevusSkin pathologyMelanomaSkinNevus Pigmentedmedicine.diagnostic_testbusiness.industryMelanomaLiver NeoplasmsMiddle Agedmedicine.diseaseDermatologyNivolumabTreatment Outcome030220 oncology & carcinogenesisFemaleNivolumabTomography X-Ray ComputedbusinessInternational Journal of Dermatology
researchProduct

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

2010

Resection of intact primary tumor is controversial in metastatic breast cancer patients. The aim of this study is to review the impact of surgical resection of primary tumor on overall survival and to assess the role of timing of surgery on survival rates.208 patients with metastatic breast cancer diagnosed between 1982 and 2005 in the Hospital Clinico of Valencia (Spain) were analysed. Exclusion criteria were age80, PS 3-4, Charlson score 3 or follow-up90 days. 123 of these underwent surgery and 85 did not. In order to assess the role of timing, the "surgery" cohort was divided into two sub-groups: "before" (n = 78) or "after" (n = 45) diagnosis of disseminated disease.In the surgery group…

medicine.medical_specialtyTime FactorsBreast surgerymedicine.medical_treatmentBreast NeoplasmsmedicineHumansNeoplasm MetastasisMastectomySurvival analysisNeoplasm StagingRetrospective StudiesUnivariate analysisPerformance statusbusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseDebulkingSurvival AnalysisPrimary tumorMetastatic breast cancerSurgeryCarcinoma LobularTreatment OutcomeSpainFemaleSurgerybusinessMastectomyThe Breast
researchProduct

Beidseitige progrediente Hörminderung als Erstmanifestation eines metastasierenden Pankreaskopfkarzinoms - Kasuistik -

2001

We report the history of a patient who presented first with a progressive unilateral hearing loss and later with a bilateral deafness and an unilateral facial nerve palsy as first and only symptoms of a pancreatic adenocarcinoma. By means of magnetic resonance tomography tumor-suspect lesions in both internal auditory canals were detected. Referring to the results of further examinations these intracanalicular lesions are most probably due to rarely seen bilateral metastasis of a pancreatic adenocarcinoma in the temporal bone. In addition to this rarely diagnosed localisation of metastasis it is rather uncommon that this kind of primary malignoma had not been detected because of gastrointes…

medicine.medical_specialtybusiness.industryHearing lossBilateral Deafnessmedicine.diseaseFacial nerveFacial paralysisSurgeryMetastatic carcinomamedicine.anatomical_structureOtorhinolaryngologyInternal auditory meatusTemporal boneMedicinemedicine.symptomUnilateral hearing lossbusinessLaryngo-Rhino-Otologie
researchProduct